Sugi Predict

Sugi Predict / Compounds / SCHEMBL40056

SCHEMBL40056

SCHEMBL40056

CC(C)(C)OC(=O)N1CCC[C@H](C(=O)O)C1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.64
▸ ALDH1A1 P00352 1/20 0.64
▸ MAPT P10636 1/20 0.64
▸ KMT2A Q03164 1/20 0.64
▸ HPGD P15428 1/20 0.59
▸ HSD17B10 Q99714 1/20 0.55
▸ EPHX1 P07099 1/20 0.49
▸ HSD11B1 P28845 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ USP30 Q70CQ3 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ ABL1 P00519 1/20 0.44
▸ RIN1 Q13671 1/20 0.44
▸ BTK Q06187 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ PREP P48147 1/20 0.43
▸ GLS O94925 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40057 1.00 MEN1 (0.64) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL181768 1.00 MEN1 (0.64) MEN1ALDH1A1MAPTKMT2AHPGD
Hydrazine SCHEMBL27951659 0.97 MEN1 (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL18391126 0.95 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL30769887 0.95 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL31421106 0.95 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL1439980 0.95 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL3919651 0.94 HPGD (0.61) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL27963722 0.94 HPGD (0.65) MEN1ALDH1A1MAPTKMT2AHPGD
SCHEMBL42957 0.90 HPGD (0.62) MEN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 447 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016029146-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON (US) 2016-02-25 — — WO claimed
EP-4735430-A1 MALT1 INHIBITORS Janssen Pharmaceutica NV (BE) 2026-05-06 — — EP disclosed
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof MBD Co., Ltd. (KR) 2026-04-28 — — US disclosed
US-20260109698-A1 MALT-1 MODULATORS EXSCIENTIA AI LIMITED (GB) 2026-04-23 — — US disclosed
US-12583839-B2 PD-L1 antagonist compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2026-03-24 — — US disclosed
EP-4709720-A1 INHIBITORS AND DEGRADERS OF PIP4K PROTEIN Larkspur Biosciences, Inc. (US) 2026-03-18 — — EP disclosed
EP-4695236-A1 SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE Soley Therapeutics, Inc. (US) 2026-02-18 — — EP disclosed
EP-4688738-A1 HETEROCYCLOALKYL BETA-HYDROXY ALKYL AMINES FOR USE IN THE TREATMENT OF HYPERGLYCAEMIA AND DISORDERS CHARACTERISED BY HYPERGLYCAEMIA Atrogi AB (SE) 2026-02-11 — — EP disclosed
EP-4192833-B1 PHARMACOLOGICALLY ACTIVE HETEROCYCLIC-SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES RICHTER GEDEON NYRT (HU) 2026-01-21 — — EP disclosed
US-12492200-B2 NLRP3 modulators Birstol Myers-Squibb Company (US) 2025-12-09 — — US disclosed
WO-2005044797-A1 ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2005-05-19 — — WO disclosed
US-20040220238-A1 Pyrrolidine oxadiazole-and thiadiazole derivatives MERCK SERONO SA (CH) 2004-11-04 — — US disclosed
WO-2004035556-A1 SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS GLAXO GROUP LIMITED (GB) 2004-04-29 — — WO disclosed
US-6127366-A ANTICARCINOGENIC OR ANTITUMOR AGENTS MERCK & CO., INC. (US) 2000-10-03 — — US disclosed
EP-0862435-A4 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO INC (US) 1999-02-03 — — EP disclosed
US-5817678-A IMIDAZOLE-CONTAINING PIPERIDINE DERIVATIVES, PEPTIDEMIMETIC MERCK & CO., INC. (US) 1998-10-06 — — US disclosed
EP-0862435-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1998-09-09 — — EP disclosed
WO-1997018813-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-05-29 — — WO disclosed
WO-1996032943-A1 3-SUBSTITUTED PIPERIDINES PROMOTE RELEASE OF GROWTH HORMONE MERCK & CO., INC. (US) 1996-10-24 — — WO disclosed
US-5559128-A FOOD ANIMALS; MEDICAL DIAGNOSIS MERCK & CO., INC. (US) 1996-09-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220238-A1 Pyrrolidine oxadiazole-and thiadiazole derivatives OXTR, PRLHR, PGF MEN1 4838/4885ALDH1A1 1541/4885MAPT 4319/4885
US-12612384-B2 Heterocyclic CYP4A inhibitor compounds and compositions thereof CYP4A11, CYP4B1, CYP4A22 MEN1 4640/4885ALDH1A1 217/4885MAPT 2797/4885
US-12492200-B2 NLRP3 modulators NLRP3, NLRP1, PYCARD MEN1 3090/4885ALDH1A1 864/4885MAPT 1594/4885
US-20260109698-A1 MALT-1 MODULATORS MALT1, BCL6, BCL3 MEN1 2473/4885ALDH1A1 3054/4885MAPT 4828/4885
US-12583839-B2 PD-L1 antagonist compound CD274, PDCD1LG2, PDCD1 MEN1 4166/4885ALDH1A1 747/4885MAPT 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.